Analysts See $-0.89 EPS for Aerie Pharmaceuticals, Inc. (AERI)

April 20, 2018 - By Clifton Ray

Investors sentiment decreased to 1.2 in 2017 Q4. Its down 0.53, from 1.73 in 2017Q3. It turned negative, as 23 investors sold Aerie Pharmaceuticals, Inc. shares while 48 reduced holdings. 21 funds opened positions while 64 raised stakes. 34.86 million shares or 1.29% more from 34.42 million shares in 2017Q3 were reported.
Tradewinds Cap Mngmt Limited Liability holds 185 shares or 0.01% of its portfolio. Swiss State Bank has 0% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Rice Hall James & Associates Ltd, California-based fund reported 269,161 shares. C Ww Gru Hldg A S has 0.07% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 82,188 shares. New York-based Sg Americas Secs Limited Company has invested 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Castleark Mgmt Ltd Liability Corporation holds 0.08% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 45,223 shares. Stifel Corp holds 85,458 shares. Vanguard Group Inc Inc stated it has 3.06M shares. Orbimed Lc reported 1.33M shares. Bamco Ny reported 7,351 shares. Financial Consulate Inc, Maryland-based fund reported 10,500 shares. Mirae Asset Ltd stated it has 0.03% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Great West Life Assurance Company Can reported 4,160 shares or 0% of all its holdings. State Street Corp holds 803,008 shares or 0% of its portfolio. Next Century Growth Investors Limited Liability Co has 0.69% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Analysts expect Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to report $-0.89 EPS on May, 1.They anticipate $0.13 EPS change or 17.11 % from last quarter’s $-0.76 EPS. After having $-1.38 EPS previously, Aerie Pharmaceuticals, Inc.’s analysts see -35.51 % EPS growth. The stock decreased 1.01% or $0.55 during the last trading session, reaching $53.95. About 150,582 shares traded. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has risen 16.25% since April 20, 2017 and is uptrending. It has outperformed by 4.70% the S&P500.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Among 8 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals had 11 analyst reports since October 24, 2017 according to SRatingsIntel. The stock has “Buy” rating by Canaccord Genuity on Wednesday, January 24. Cantor Fitzgerald maintained the stock with “Buy” rating in Monday, December 18 report. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given on Wednesday, February 28 by Cantor Fitzgerald. Stifel Nicolaus maintained the stock with “Buy” rating in Tuesday, January 2 report. The firm earned “Buy” rating on Thursday, November 16 by Cantor Fitzgerald. The rating was reinitiated by H.C. Wainwright with “Buy” on Friday, February 16. Mizuho maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating on Thursday, March 29. Mizuho has “Buy” rating and $8700 target. On Thursday, November 9 the stock rating was maintained by Cowen & Co with “Buy”. On Thursday, March 1 the stock rating was maintained by H.C. Wainwright with “Buy”.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. The company has market cap of $2.13 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It currently has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.